A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Single and Multiple Doses of Spironolactone Oral Suspension in Pediatric Patients With Edema Due to Heart Failure or Cirrhosis
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Spironolactone (Primary)
- Indications Oedema
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors CMP Pharma
Most Recent Events
- 27 Sep 2023 Status changed from completed to not yet recruiting.
- 05 Sep 2023 New trial record